



the **Hydroponics** company

www.thcl.com.au

ASX RELEASE (2 March 2018)

THC WELCOMES SIMPLIFIED ACCESS TO MEDICINAL CANNABIS IN NSW

Key Points:

- **NSW Government to streamline approval process for doctors and patients requiring medicinal cannabis**
- **Single clinical assessment by Therapeutic Goods Administration will significantly shorten the time between application and approval for doctors in NSW to prescribe medicinal cannabis**
- **THC recently granted approval to import medicinal cannabis products from European partner Endoca**

The Hydroponics Company Limited (ASX:THC) (“**THC**”) welcomes plans announced today by the New South Wales Government to streamline the approval process for doctors and patients in NSW to access medicinal cannabis treatment. Instead of both the Commonwealth and NSW Health overseeing the approvals, NSW will rely on a single clinical assessment by the Therapeutic Goods Administration (TGA).

Please see the link below to visit the announcement

http://www.health.nsw.gov.au/news/Pages/20180302_00.aspx

A single approval process effectively streamlines the application process and means that doctors wanting to prescribe unregistered cannabis medicines would typically get approval within 36 hours. The arrangement which will start in the coming weeks removes barriers and ends a duplication of regulatory requirements.

This announcement follows THC’s recent approval by the Office of Drug Control to commence importing high quality medicinal cannabis products under its distribution agreement with European supplier Endoca.



The Hydroponics Company Limited
(ASX:THC) ACN: 614 508 039

Suite 305, Level 3, 35 Lime St
Sydney, NSW, Australia. 2000.


For further information, please contact:



David Radford
Group Chief Executive Officer
The Hydroponics Company Limited

Suite 305, Level 3, 35 Lime Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177
M: +61 407 218 922
E: davidr@thcl.com.au



Michael Lovesey
Director Corporate Media Relations
MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177
M: +61 449 607 636
E: michaell@mmercporate.com

About The Hydroponics Company www.thcl.com.au

THC is at the forefront of developing a leading, diversified worldwide cannabis business, focusing on two core business units: Development and delivery of medicinal cannabis, and manufacturing and distribution of hydroponics equipment, materials and nutrients.

About Canndeo Ltd www.canndeo.com

Canndeo is a wholly-owned subsidiary of THC that operates under a pharmaceutical model with a focus on the end-to-end supply of medicinal cannabis products. THC has leading expertise in breeding, growth and extraction capability with a focus on the rapid introduction of medicinal cannabis products. It has received its Medicinal Cannabis Research Licence in July, 2017 and its Medicinal Cannabis Licence in Oct 2017. Canndeo leverages +17 years of Cannabis sativa breeding, variety selection and growth management. Canndeo will target multiple medical markets with high purity cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.